1. Home
  2. PRSO vs INAB Comparison

PRSO vs INAB Comparison

Compare PRSO & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Peraso Inc.

PRSO

Peraso Inc.

HOLD

Current Price

$0.30

Market Cap

13.4M

Sector

Technology

ML Signal

HOLD

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$0.82

Market Cap

11.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRSO
INAB
Founded
2008
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.4M
11.8M
IPO Year
2000
2020

Fundamental Metrics

Financial Performance
Metric
PRSO
INAB
Price
$0.30
$0.82
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $7.00
AVG Volume (30 Days)
★ 11.7M
64.9K
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 81.23
N/A
EPS
★ N/A
N/A
Revenue
★ $14,573,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$191.73
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 5.99
N/A
52 Week Low
$0.28
$0.72
52 Week High
$2.10
$2.73

Technical Indicators

Market Signals
Indicator
PRSO
INAB
Relative Strength Index (RSI) 36.98 37.93
Support Level N/A N/A
Resistance Level $0.46 $1.50
Average True Range (ATR) 0.04 0.08
MACD -0.01 -0.00
Stochastic Oscillator 10.38 36.65

Price Performance

Historical Comparison
PRSO
INAB

About PRSO Peraso Inc.

Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices, and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz to 300 GHz. Geographically, the company generates revenue from the United States, Hong Kong, Taiwan, Europe, and the Rest of the World.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: